Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bartsch

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
Geburtshilfe Und Frauenheilkunde|October 7, 2014
Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus ConferenceM Hubalek, R Bartsch, M Gnant, et al.
British Journal of Cancer|January 12, 2012
Brain metastases free survival differs between breast cancer subtypesA Berghoff, Z Bago-Horvath, C De Vries, et al.
ESMO Open|April 1, 2026
Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from AustriaN Dobrić, S O Hasenleithner, C Suppan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industryR Bartsch, S Frings, M Marty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2013
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)G G Steger, R Greil, A Lang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2013
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy aloneM Gnant, M Filipits, R Greil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12M Gnant, B Mlineritsch, H Stoeger, et al.
Epidemiology and Psychiatric Sciences|October 17, 2022
Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional studyE L Zeilinger, C Oppenauer, M Knefel, et al.
ESMO Open|January 4, 2025
Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasisR Bartsch, J M Pérez-García, J Furtner, et al.
ESMO Open|December 23, 2022
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study GroupS P Gampenrieder, V Dezentjé, M Lambertini, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Geburtshilfe Und Frauenheilkunde|October 7, 2014
Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus ConferenceM Hubalek, R Bartsch, M Gnant, et al.
British Journal of Cancer|January 12, 2012
Brain metastases free survival differs between breast cancer subtypesA Berghoff, Z Bago-Horvath, C De Vries, et al.
ESMO Open|April 1, 2026
Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from AustriaN Dobrić, S O Hasenleithner, C Suppan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industryR Bartsch, S Frings, M Marty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2013
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)G G Steger, R Greil, A Lang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2013
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy aloneM Gnant, M Filipits, R Greil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12M Gnant, B Mlineritsch, H Stoeger, et al.
Epidemiology and Psychiatric Sciences|October 17, 2022
Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional studyE L Zeilinger, C Oppenauer, M Knefel, et al.
ESMO Open|January 4, 2025
Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasisR Bartsch, J M Pérez-García, J Furtner, et al.
ESMO Open|December 23, 2022
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study GroupS P Gampenrieder, V Dezentjé, M Lambertini, et al.
Pageof 12